Clinical Course and Treatment Implications of Combination Immune Checkpoint Inhibitor-Mediated Hepatitis: A Multicentre Cohort

BACKGROUND: Immune-related adverse events can occur after treatment with immune checkpoint inhibitors (ICI), limiting treatment persistence. We aimed to evaluate the clinical course of ICI-mediated hepatitis (IMH) associated with combination ipilimumab and nivolumab treatment. METHODS: A retrospecti...

Descripción completa

Detalles Bibliográficos
Autores principales: Smith, Matthew K, Chan, Yin, Suo, Aleksi E, Shaheen, Abdel Aziz, Congly, Stephen E, Tandon, Puneeta, Bhanji, Rahima A, Wells, Malcolm M, Cheng, Tina, Ma, Christopher
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2021
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8806044/
https://www.ncbi.nlm.nih.gov/pubmed/35118226
http://dx.doi.org/10.1093/jcag/gwab019

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8806044/
https://www.ncbi.nlm.nih.gov/pubmed/35118226
http://dx.doi.org/10.1093/jcag/gwab019

Ejemplares similares